RPL35

Large ribosomal subunit protein uL29 · P42766 · RPL35 on Sugi Atlas →

3,673 patent compounds predicted against RPL35, 1,924 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL35 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection	PHASE2	UNKNOWN
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	PHASE2	RECRUITING
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE2	NOT_YET_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors	PHASE1	ACTIVE_NOT_RECRUITING
A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection	PHASE1	COMPLETED
Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)	PHASE1	WITHDRAWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection	nan	UNKNOWN
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus	nan	COMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults	nan	COMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.	nan	UNKNOWN
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Gene Expression in Inflammatory Bowel Disease	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a RPL35 binder may also engage these)

Protein	Name	Similarity
P17078	—	1.000	P17078 →
G1SIT5	—	1.000	G1SIT5 →
Q6UZF7	—	1.000	Q6UZF7 →
Q5DVH6	—	1.000	Q5DVH6 →
Q6PBC1	—	0.999	Q6PBC1 →
Q3MHM7	—	0.999	Q3MHM7 →
Q6ZWV7	—	0.998	Q6ZWV7 →
Q69CJ9	—	0.998	Q69CJ9 →
Q98TF7	—	0.998	Q98TF7 →
Q29361	—	0.998	Q29361 →
Q9M5L0	—	0.997	Q9M5L0 →
Q8JHJ1	—	0.995	Q8JHJ1 →
Q9M3D2	—	0.995	Q9M3D2 →
Q8L805	—	0.993	Q8L805 →
Q90YT4	—	0.992	Q90YT4 →
P34662	—	0.992	P34662 →
Q54J23	—	0.991	Q54J23 →
P0CX84	—	0.989	P0CX84 →
Q9LZ41	—	0.988	Q9LZ41 →
Q9SF53	—	0.987	Q9SF53 →
P52817	—	0.987	P52817 →
P0CX85	—	0.986	P0CX85 →
A0A1D8PK30	—	0.985	A0A1D8PK30 →
P0DJ51	—	0.985	P0DJ51 →
O80626	—	0.984	O80626 →
Q4N756	—	0.982	Q4N756 →
O74904	—	0.982	O74904 →
Q2VA69	—	0.979	Q2VA69 →
Q4UIF8	—	0.976	Q4UIF8 →
Q8SQQ7	—	0.974	Q8SQQ7 →